MCID: ART008
MIFTS: 42

Arteriosclerosis Obliterans malady

Category: Cardiovascular diseases

Aliases & Classifications for Arteriosclerosis Obliterans

About this section

Aliases & Descriptions for Arteriosclerosis Obliterans:

Name: Arteriosclerosis Obliterans 11 50 39 13 68

Classifications:



External Ids:

Disease Ontology11 DOID:5160
SNOMED-CT62 361133006, 60625000
MeSH39 D001162

Summaries for Arteriosclerosis Obliterans

About this section
Wikipedia:71 Arteriosclerosis obliterans is an occlusive arterial disease most prominently affecting the abdominal... more...

MalaCards based summary: Arteriosclerosis Obliterans is related to myocardial infarction and arteriosclerosis. An important gene associated with Arteriosclerosis Obliterans is SELP (Selectin P), and among its related pathways are LDL Oxidation in Atherogenesis and Transcription factor regulation in adipogenesis. The drugs tolazoline and tolazoline hydrochloride have been mentioned in the context of this disorder. Affiliated tissues include heart, smooth muscle and skin, and related mouse phenotypes are cardiovascular system and cellular.

Related Diseases for Arteriosclerosis Obliterans

About this section

Diseases related to Arteriosclerosis Obliterans via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 71)
idRelated DiseaseScoreTop Affiliating Genes
1myocardial infarction29.6ADIPOQ, ICAM1, IL6, SELP, VCAM1
2arteriosclerosis10.9
3cryptosporidiosis10.2IL6, SELP
4latent syphilis10.2ICAM1, IL6
5neuroaxonal dystrophy10.2ICAM1, IL6
6macrodactyly of the foot10.2ICAM1, VCAM1
7periosteal chondrosarcoma10.2ICAM1, VCAM1
8right ventricle hypoplasia10.2ICAM1, VCAM1
9phlegmonous dacryocystitis10.1ICAM1, VCAM1
10aneurysm10.1
11ovarian clear cell malignant adenofibroma10.1ICAM1, VCAM1
12dislocation of ear ossicle10.1ICAM1, VCAM1
13congenital chloride diarrhea10.1IL6, SELP, VCAM1
14heart disease10.1
15lymphedema10.1ICAM1, VCAM1
16ependymoblastoma10.1ICAM1, SELP, VCAM1
17xerophthalmia10.1ICAM1, SELP, VCAM1
18conduct disorder10.1ICAM1, IL6
19gait apraxia10.1ADIPOQ, ICAM1, IL6
20intra-abdominal lymph node mast cell malignancy10.1ICAM1, SELP, VCAM1
21erb-duchenne and dejerine-klumpke palsies10.1ICAM1, IL6, VCAM1
22lymph node disease10.1ICAM1, ITGA4
23multilocular clear cell renal cell carcinoma10.1ICAM1, IL6
24pemphigus vulgaris, familial10.1ICAM1, IL6, VCAM1
25ischemic optic neuropathy10.1HTR2A, IL6, SELP
26synovium cancer10.1ICAM1, IL6, VCAM1
27pigmentation disease10.1ICAM1, IL6, VCAM1
28ischemia10.1
29aortic aneurysm10.1
30degenerative disc disease10.0HGF, IL6
31mucinoses10.0ADIPOQ, IL6, SELP, VCAM1
32artery disease10.0
33hypopyon ulcer10.0ICAM1, ITGA4, VCAM1
34diabetes mellitus, insulin-dependent, 2010.0ADIPOQ, IL6, SELP, VCAM1
35cervix small cell carcinoma10.0ICAM1, IL6, SELP, VCAM1
36pyriform sinus cancer9.9ICAM1, IL6
37autoimmune-related retinopathy and optic neuropathy9.9ADIPOQ, ICAM1, IL6, VCAM1
38pericarditis9.9ADIPOQ, SELP, VCAM1
39immunodeficiency due to defect in mapbp-interacting protein9.9ICAM1, IL6, SELP, VCAM1
40diabetic encephalopathy9.9ADIPOQ, HTR2A, ICAM1, IL6
41atherosclerosis9.9
42intermittent claudication9.9
43ischemic heart disease9.9
44peripheral artery disease9.9
45cerebritis9.9
46abdominal aortic aneurysm9.9
47maturity-onset diabetes of the young 69.9ADIPOQ, IL6, SELP, VCAM1
48epidermolysis bullosa simplex, sutosomal recessive 29.9HGF, ICAM1, VCAM1
49lymphoid leukemia9.9ADIPOQ, HGF, IL6
50perrault syndrome9.9ICAM1, ITGA4, SELP, VCAM1

Graphical network of the top 20 diseases related to Arteriosclerosis Obliterans:



Diseases related to arteriosclerosis obliterans

Symptoms & Phenotypes for Arteriosclerosis Obliterans

About this section

MGI Mouse Phenotypes related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053858.2ADIPOQ, HGF, ICAM1, IL6, ITGA4, SELP
2MP:00053848.1ADIPOQ, HGF, ICAM1, IL6, ITGA4, SELP
3MP:00053977.4ADIPOQ, HGF, ICAM1, IL6, ITGA4, SELP

Drugs & Therapeutics for Arteriosclerosis Obliterans

About this section

Drugs for Arteriosclerosis Obliterans (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 57)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Aspirinapproved, vet_approvedPhase 4115250-78-22244
Synonyms:
11126-35-5
11126-37-7
1oxr
2-(Acetyloxy)benzoate
2-(Acetyloxy)benzoic acid
2-Acetoxybenzenecarboxylic acid
2-Acetoxybenzoate
2-Acetoxybenzoic acid
2-Carboxyphenyl acetate
2349-94-2
26914-13-6
50-78-2
8-hour Bayer
98201-60-6
A 5376
A.S.A
A.S.A.
A.S.A. Empirin
A.S.A. empirin
A2093_SIGMA
A3160_SIGMA
A5376_SIGMA
A6810_SIGMA
AB1003266
AC 5230
AC1L1D8U
AC1Q1LA0
ACETYLSALICYLIC ACID
AI3-02956
AIN
AKOS000118884
ASA
Acenterine
Acesal
Acetal
Acetard
Aceticyl
Acetilsalicilico
Acetilum acidulatum
Acetisal
Acetol
Acetonyl
Acetophen
Acetosal
Acetosalic acid
Acetosalin
Acetoxybenzoic acid
Acetylin
Acetylsal
Acetylsalicylate
Acetylsalicylic acid
Acetylsalicylsaeure
Acetylsalicylsaure
Acetylsalicylsäure
Acetylsalycilic acid
Acetyonyl
Acetysal
Acetysalicylic acid
Acide acetylsalicylique
Acido O-acetil-benzoico
Acido acetilsalicilico
Acidum acetylsalicylicum
Acimetten
Acisal
Acylpyrin
Adiro
Aloxiprimum
Asacard
Asagran
Asatard
Ascoden-30
Aspalon
Aspec
Aspergum
Aspir-Mox
Aspirdrops
Aspirin
Aspirin (JP15/USP)
Aspirin [BAN:JAN]
Aspirina 03
Aspirine
Asprin
Aspro
Aspro Clear
Asteric
Azetylsalizylsaeure
Azetylsalizylsäure
BIDD:GT0118
BRN 0779271
Bay-e-4465
Bayer
Bayer Aspirin 8 Hour
Bayer Buffered
Bayer Extra Strength Aspirin For Migraine Pain
Bayer Plus
Benaspir
Bi-prin
Bialpirina
Bialpirinia
Bufferin
C01405
CCRIS 3243
CHEBI:15365
CHEMBL25
CID2244
Caprin
Cardioaspirin
Cardioaspirina
Cemirit
Claradin
Clariprin
Colfarit
Contrheuma retard
Coricidin
Crystar
D00109
D001241
DB00945
Decaten
Delgesic
Dispril
DivK1c_000555
Dolean pH 8
Duramax
ECM
EINECS 200-064-1
EU-0100038
Easprin
Easprin (TN)
Ecolen
Ecotrin
Empirin
Empirin with Codeine
Endosprin
Endydol
Entericin
Enterophen
 
Enterosarein
Enterosarine
Entrophen
Extren
Globentyl
Globoid
HMS1920E13
HMS2090G03
HMS2091K13
HMS501L17
HSDB 652
Helicon
I14-7505
IDI1_000555
Idragin
Istopirin
KBio1_000555
KBio2_001725
KBio2_002271
KBio2_004293
KBio2_004839
KBio2_006861
KBio2_007407
KBio3_002149
KBio3_002751
KBioGR_000398
KBioGR_002271
KBioSS_001725
KBioSS_002272
Kapsazal
Kyselina 2-acetoxybenzoova
Kyselina acetylsalicylova
LS-143
Levius
Lopac-A-5376
Lopac0_000038
MLS001055329
MLS001066332
MLS001336045
MLS001336046
Magnecyl
Measurin
Medisyl
Micristin
MolPort-000-871-622
NCGC00015067-01
NCGC00015067-04
NCGC00015067-09
NCGC00090977-01
NCGC00090977-02
NCGC00090977-03
NCGC00090977-04
NCGC00090977-05
NCGC00090977-06
NCGC00090977-07
NCI60_002222
NINDS_000555
NSC 27223
NSC27223
NSC406186
Neuronika
Novid
Nu-seals
Nu-seals aspirin
O-(Acetyloxy)benzoate
O-(Acetyloxy)benzoic acid
O-Acetoxybenzoate
O-Acetoxybenzoic acid
O-Acetylsalicylic acid
O-Carboxyphenyl acetate
O-accetylsalicylic acid
O-acetylsalicylic acid
PL-2200
Persistin
Pharmacin
Pirseal
Polopirin
Polopiryna
Premaspin
R16CO5Y76E [UNII]
Rheumin tabletten
Rheumintabletten
Rhodine
Rhonal
Ronal
S-211
SMR000059138
SP 189
SPBio_001838
SPECTRUM1500130
ST075414
Salacetin
Salcetogen
Saletin
Salicylic acid acetate
Salicylic acid, acetate
Salospir
Solfrin
Solprin
Solprin acid
Solpyron
Solupsan
Spectrum2_001899
Spectrum3_001295
Spectrum4_000099
Spectrum5_000740
Spectrum_001245
Spira-Dine
St. Joseph
St. Joseph Aspirin for Adults
Supac
Tasprin
Temperal
Toldex
Triaminicin
Triple-sal
UNII R16CO5Y76E
UNII-R16CO5Y76E
UNII=R16CO5Y76E
UNM-0000306102
Vanquish
WLN: QVR BOV1
XAXA
Xaxa
Yasta
ZORprin
acide 2-(acétyloxy)benzoïque
acide acétylsalicylique
aspirin
cMAP_000006
component of Midol
component of Synirin
nchem.859-comp6
o-Acetoxybenzoic acid
o-Carboxyphenyl acetate
o-acetoxybenzoic acid
o-carboxyphenyl acetate
salicylic acid acetate
ácido acetilsalicílico
2
CilostazolapprovedPhase 410673963-72-12754
Synonyms:
3,4-Dihydro-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone
3,4-dihydro-6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-2(1H)-quinolinone
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydrocarbostyril
6-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxyl)-3,4-dihydrocarobostyril
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-1H-quinolin-2-one
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone
6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydroquinolin-2(1H)-one
6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-3,4-dihydro-1H-quinolin-2-one
73963-72-1
89332-50-3
AC-4334
AC1L1EE2
BRD-K67017579-001-04-2
BRD-K67017579-001-05-9
BRD-K67017579-001-07-5
BRD-K67017579-001-13-3
BRN 3632107
BSPBio_002759
C 0737
C045645
C0737_SIGMA
C20H27N5O2
CHEBI:31401
CHEMBL799
CID2754
CL23867
CPD000058428
Cilostazol (JP15/USAN/INN)
Cilostazol [INN:JAN]
Cilostazole
Cilostazolum
Cilostazolum [INN-Latin]
D01896
DB01166
EU-0100218
HMS1922N15
HMS2093M14
KBio3_002259
KBioGR_001184
 
LS-142693
Lopac-C-0737
Lopac0_000218
MLS000028470
MLS000758281
MLS000759507
MLS001076067
MLS002153891
MolPort-001-758-007
NCGC00015207-01
NCGC00015207-02
NCGC00015207-06
NCGC00015207-10
NCGC00022153-02
NCGC00022153-04
NCGC00022153-05
NCGC00022153-06
NCGC00022153-07
OPC 13013
OPC 21
OPC-13013
OPC-21
Otsuka brand of cilostazol
Pletaal
Pletal
Pletal (TN)
Pletal, Cilostazol
S1294_Selleck
SAM001246734
SAM001247085
SMR000058428
SPBio_001256
SPECTRUM1505230
Spectrum2_001118
Spectrum3_001170
Spectrum4_000772
Spectrum5_001762
TL8005113
Tocris-1692
UNII-N7Z035406B
ZINC01552174
cilostazol
3
Valsartanapproved, investigationalPhase 4295137862-53-460846
Synonyms:
(2S)-3-methyl-2-[pentanoyl-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]amino]butanoic acid
(S)-N-Valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
(S)-N-valeryl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]-methyl}-valine
(s)-2-(n-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)pentanamido)-3-methylbutanoic acid
137862-53-4
AC-4543
AC1L1U1M
AC1Q5QIK
Ambap137862-53-4
Aventis brand of valsartan
BIDD:GT0345
BRD-K45158365-001-02-3
BSPBio_003501
Bio-0796
C081489
C24H29N5O3
CEPA brand of valsartan
CGP 48933
CGP-48933
CHEBI:9927
CHEMBL1069
CID60846
CPD000466318
D00400
DB00177
Diovan
Diovan (TN)
Diovan, Valsartan
Esteve brand of valsartan
HMS1922L21
HMS2051L12
HMS2093K22
HSDB 7519
KBio2_002287
KBio2_004855
KBio2_007423
KBio3_003006
KBioGR_001078
KBioSS_002289
 
Kalpress
L-Valine, N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (9CI)
LS-161334
Lacer brand of valsartan
MLS000759423
MLS001424088
Miten
MolPort-002-507-854
MolPort-003-666-608
N-(1-oxopentyl)-N-[[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-L-valine
N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine
N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-L-valine
N-pentanoyl-N-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-L-valine
N-valeryl-N-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)valine
Nisis
Nisis||
Novartis brand of valsartan
Provas
S1894_Selleck
SAM001246581
SMR000466318
SPBio_001260
SPECTRUM1505209
Sanol brand of valsartan
Schwarz brand of valsartan
Spectrum2_001120
Spectrum3_001831
Spectrum4_000749
Spectrum5_001582
Spectrum_001796
TL8000869
Tareg
UNII-80M03YXJ7I
Vals
Valsarran
Valsartan (JAN/USAN/INN)
Valsartan [USAN:INN]
valsartan
walsartan
|Tareg
4
ProbucolapprovedPhase 42223288-49-54912
Synonyms:
2,6-ditert-butyl-4-[2-(3,5-ditert-butyl-4-hydroxyphenyl)sulfanylpropan-2-ylsulfanyl]phenol
23288-49-5
4,4'- (Isopropylidenedithio)bis(2, 6-di-tert-butylphenol)
4,4'- (Isopropylidenedithio)bis(2,6-di-tert-butylphenol)
4,4'-(Isopropylidenedithio)bis(2, 6-di-tert-butylphenol)
4,4'-(Isopropylidenedithio)bis(2,6-di-tert-butylphenol)
4,4'-(Isopropylidenedithio)bis[2, 6-di-tert-butylphenol]
4,4'-(Isopropylidenedithio)bis[2,6-di-tert-butylphenol]
4,4'-(propane-2,2-diyldisulfanediyl)bis(2,6-di-tert-butylphenol)
4,4'-[(1-Methylethylidene)bis(thio)]bis-[2,6-bis(1,1-dimethylethyl)phenol]
AB00052202
AC1L1J88
AKOS001740866
Acetone bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole
Acetone, bis (3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole
Acetone, bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole
Almirall Brand of Probucol
Aventis Brand of Probucol
BPBio1_000625
BRN 2026253
BSPBio_000567
BSPBio_003176
Biphenabid
Bisbid
Bisphenabid
C07373
C31H48O2S2
CAS-23288-49-5
CCRIS 7510
CHEBI:122641
CHEMBL608
CID4912
D00476
D011341
DB01599
DE-3872
DH 581
DH-581
DH581
DivK1c_000599
EINECS 245-560-9
HMS1569M09
HMS1921D21
HMS2092D05
HMS501N21
Hoechst Brand of Probucol
IDI1_000599
KBio1_000599
KBio2_001776
KBio2_002394
KBio2_004344
KBio2_004962
KBio2_006912
KBio2_007530
 
KBio3_002396
KBio3_002873
KBioGR_000708
KBioGR_002394
KBioSS_001776
KBioSS_002399
LORELCO (TN)
LS-13188
Lesterol
Lorelco
Lursell
Lurselle
MLS000028492
MolPort-002-042-265
NCGC00016777-01
NCGC00094895-01
NCGC00094895-02
NCGC00094895-03
NCGC00094895-04
NINDS_000599
NSC 652160
NSC 86225
NSC652160
NSC86225
P9672_FLUKA
P9672_SIGMA
Panavir
Prestwick0_000384
Prestwick1_000384
Prestwick2_000384
Prestwick3_000384
Prestwick_408
Probucol (JAN/USP/INN)
Probucol [USAN:BAN:INN:JAN]
Probucolum
Probucolum [INN-Latin]
Probucolum [inn-latin]
SMR000058265
SPBio_001420
SPBio_002488
SPECTRUM1501109
ST075698
STK762566
Serterol
Sinlestal
Spectrum2_001400
Spectrum3_001438
Spectrum4_000414
Spectrum5_001343
Spectrum_001296
Superlipid
UNII-P3CTH044XJ
ZERO/001429
ZINC01530755
cMAP_000039
probucol
5
RemifentanilapprovedPhase 4471132875-61-760815
Synonyms:
1-Piperidinepropanoic acid, 4-(methoxy-carbonyl)-4-((1-oxopropyl)phenylamino)-, methyl ester
132539-07-2 (mono-hydrochloride)
132875-61-7
3-(4-methoxycarbonyl-4-((1-oxopropyl)phenylamino)-1-piperidine)propanoic acid methyl ester
4-carboxy-4-(n-phenylpropionamido)-1-piperidinepropionic acid dimethyl ester
AC1L1TZ8
AC1Q5ZGR
BIDD:GT0029
C08021
CHEBI:8802
CHEMBL1005
CID60815
D08473
DB00899
 
DEA No. 9739
GI 87084B
GI 87084X
GI87084B
L001266
LS-115982
MolPort-004-286-006
REMIFENTANIL
Remifentanil (INN)
Remifentanil [INN:BAN]
Remifentanyl
UNII-P10582JYYK
Ultiva
Ultiva (TN)
methyl 1-(3-methoxy-3-oxopropyl)-4-(N-propanoylanilino)piperidine-4-carboxylate
6
Sevofluraneapproved, vet_approvedPhase 450828523-86-65206
Synonyms:
1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane
28523-86-6
AC-15484
AC1L1JU0
BRN 2041023
Bax 3084
C009250
C07520
C4H3F7O
CHEBI:9130
CHEMBL1200694
CID5206
D00547
DB01236
F0691
Fluoromethyl 1,1,1,3,3,3-Hexafluoroisopropyl Ether
Fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
I14-13357
LS-67851
MR6S4
 
MR_6S4
MolPort-001-775-746
NCGC00167421-01
PC4681
Sevofluran
Sevoflurane
Sevoflurane (JAN/USAN/INN)
Sevoflurane [USAN:INN:BAN:JAN]
Sevoflurano
Sevoflurano [INN-Spanish]
Sevofluranum
Sevofluranum [INN-Latin]
Sevofrane
Sevorane
Sojourn
UNII-38LVP0K73A
Ultane
Ultane (TN)
ZINC01530810
fluoromethyl hexafluoroisopropyl ether
fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
sevoflurane
7
Propofolapproved, investigational, vet_approvedPhase 410822078-54-84943
Synonyms:
2, 6-Diisopropylphenol
2,6 Diisopropylphenol
2,6-Bis(1-methylethyl)phenol
2,6-Bis(Isopropyl)-phenol
2,6-DIISOPROPYLPHENOL
2,6-Diisopropyl phenol
2,6-Diisopropylphenol
2,6-bis(1-methylethyl)-phenol
2,6-di(propan-2-yl)phenol
2078-54-8
28449-97-0
4-06-00-03435 (Beilstein Handbook Reference)
50356-15-5
AB00513968
AC-2038
AC1L1J9Y
AC1Q1OUI
AI3-26295
AM-149
Abbott Brand of Propofol
Alpha Brand of Propofol
Ampofol
Aquafol
Astra Brand of Propofol
AstraZeneca Brand of Propofol
BIDD:GT0436
BPBio1_000950
BPBio1_000969
BRD-K82255054-001-03-5
BRN 1866484
BSPBio_000862
Biomol-NT_000248
Braun Brand of Propofol
C07523
C12H18O
CAS-2078-54-8
CCRIS 9000
CHEBI:44915
CHEMBL526
CID4943
CPD-11437
CPD000059151
Curamed Brand of Propofol
D00549
D015742
D0617
D126608
D126608_ALDRICH
DB00818
DDS-04F
Diisopropylphenol
Dipravan
Diprivan
Diprivan (TN)
Diprivan Injectable emulsion
Disoprivan
Disoprofol
EINECS 218-206-6
EU-0100437
Fresenius Brand of Propofol
Fresenius Kabi Brand of Propofol
Fresofol
HMS1570L04
HMS2089O21
HMS2094E17
 
HSDB 7123
ICI 35,868
ICI 35868
ICI-35,868
ICI-35868
ICI35,868
ICI35868
InChI=1/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H
Ivofol
Jsp004266
Juste Brand of Propofol
LS-996
Lopac-D126608
Lopac0_000437
MLS001066348
MLS001335999
MLS002454360
MolPort-001-794-517
NCGC00015389-01
NCGC00015389-02
NCGC00015389-04
NCGC00015389-09
NCGC00091538-01
NCGC00091538-02
NCGC00091538-03
NCGC00091538-04
NCGC00091538-05
NCGC00091538-06
NSC 5105
NSC5105
PFL
Parnell Brand of Propofol
Pisa Brand of Propofol
Prestwick0_000931
Prestwick1_000931
Prestwick2_000931
Prestwick3_000931
Propofol
Propofol (JAN/USAN/INN)
Propofol Abbott
Propofol Fresenius
Propofol IDD-D
Propofol MCT
Propofol Rovi
Propofol [USAN:INN:BAN]
Propofol(2,6-Diisopropylphenol)
Propofol-Lipuro
Propofolum
Propofolum [Latin]
Rapinovet
Recofol
Rovi Brand of Propofol
S01-0189
SAM002264610
SMR000059151
SPBio_003031
SPECTRUM1505022
ST50405911
Schering Brand of Propofol
UNII-YI7VU623SF
W505102_ALDRICH
ZD-0859
ZINC00968303
Zeneca Brand of Propofol
ghl.PD_Mitscher_leg0.558
nchembio.552-comp7
propofol
8Platelet Aggregation InhibitorsPhase 4, Phase 22516
9Phosphodiesterase InhibitorsPhase 41289
10Protective AgentsPhase 47443
11Respiratory System AgentsPhase 44997
12Vasodilator AgentsPhase 4, Phase 23543
13Peripheral Nervous System AgentsPhase 423689
14AnalgesicsPhase 411733
15Phosphodiesterase 3 InhibitorsPhase 4133
16Anti-Inflammatory Agents, Non-SteroidalPhase 44443
17Anti-Inflammatory AgentsPhase 410729
18Anti-Asthmatic AgentsPhase 43488
19Analgesics, Non-NarcoticPhase 46501
20Antirheumatic AgentsPhase 410956
21AntipyreticsPhase 41605
22Autonomic AgentsPhase 410150
23Cyclooxygenase InhibitorsPhase 42870
24Neuroprotective AgentsPhase 41716
25Bronchodilator AgentsPhase 42965
26Fibrinolytic AgentsPhase 42388
27Antihypertensive AgentsPhase 44207
28Natriuretic AgentsPhase 41697
29AngiotensinogenPhase 41177
30Sodium Chloride Symporter InhibitorsPhase 4452
31diureticsPhase 41418
32Angiotensin II Type 1 Receptor BlockersPhase 41091
33AntimetabolitesPhase 412054
34AntioxidantsPhase 43050
35Angiotensin-Converting Enzyme InhibitorsPhase 4724
36Anticholesteremic AgentsPhase 42025
37Hypolipidemic AgentsPhase 42785
38Angiotensin Receptor AntagonistsPhase 41191
39
Angiotensin IIPhase 4117868521-88-0, 11128-99-765143, 172198
Synonyms:
1-8-Angiotensin I
1-L-Aspasaginyl-5-L-valyl angiotensin octapeptide
Ang II
Angiotensin 2
Angiotensin II (human)
 
Angiotensin II (mouse)
Angiotonin
Asp-arg-val-TYR-ile-his-pro-phe
Human angiotensin II
Hypertensin
Ile(5)-angiotensin II
40Lipid Regulating AgentsPhase 42766
41Hypnotics and SedativesPhase 42616
42Central Nervous System DepressantsPhase 413403
43NarcoticsPhase 43646
44Analgesics, OpioidPhase 43238
45AnestheticsPhase 4, Phase 1, Phase 29596
46Anesthetics, GeneralPhase 42934
47Anesthetics, IntravenousPhase 42538
48Anesthetics, InhalationPhase 4684
49
Alprostadilapproved, investigationalPhase 271745-65-3149351
Synonyms:
(11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid
(11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid
(11alpha,13e,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid
(13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate
(13E,15S)-11alpha,15-dihydroxy-9-oxoprost-13-en-1-oic acid
(13e)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate
119314-69-1
11alpha,15alpha-Dihydroxy-9-oxo-13-trans-prostenoic acid
7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid
745-65-3
82474_FLUKA
A0593_SIAL
AB00514004
AC-6095
AC1NQXHQ
Alista
Alprostadil
Alprostadil (JP15/USP/INN)
Alprostadil Alfadex
Alprostadil Prostoglandin E1
Alprostadilum
Alprox-TD
BIDD:GT0747
BML1-F06
BPBio1_001293
BRD-K52459643-001-06-0
BSPBio_001175
BSPBio_001488
Befar
Befar (TN)
C04741
CHEBI:15544
CHEMBL495
CID5280723
CPD000112594
Caverject
D00180
DB00770
Edex
FemLife
Femprox
HEI-507
HMS1361K10
HMS1571K17
HMS1791K10
HMS1989K10
HMS2052L11
 
HMS2090L08
IDI1_033958
LMFA03010134
MLS000758964
MLS001424250
MR 256
MR-256
MolPort-003-939-183
Muse
NCGC00025234-02
NCGC00025234-03
NCGC00025234-04
NCGC00025234-05
P5515_SIAL
P5515_SIGMA
P7527_SIGMA
P8908_SIGMA
PGE-1
PGE1
PGE1 Oligomer
PGE1 α-CD
PGE₁
Prestwick2_001018
Prestwick3_001018
Prink
Prink (TN)
Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-, homopolymer
Prostaglandin E1
Prostaglandin e1
Prostavasin
Prostin VR
Prostin VR Pediatric
Prostin VR pediatric (TN)
Prostin vr
RayVa
SAM001246840
SAM001246845
SAM001247093
SMP2_000271
SMR000112594
ST50826271
Sugiran
Topiglan
U-10136
Viridal
Vitaros
alprostadil
l-Prostaglandin E1
50AnticoagulantsPhase 22623

Interventional clinical trials:

(show all 17)
idNameStatusNCT IDPhase
1Sufficient Treatment of Peripheral Intervention by CilostazolUnknown statusNCT00912756Phase 4
2Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related BiomarkerCompletedNCT00823849Phase 4
3Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study)CompletedNCT00149227Phase 4
4Diuretics In the Management of Essential Hypertension (DIME) StudyCompletedNCT00131846Phase 4
5Effects of Anesthetics on Postoperative Cognitive Function of Patients Undergoing Endovascular Repair of Aortic Aneurysm and Endovascular Treatment of Arteriosclerosis Obliterans of Lower Extremities.RecruitingNCT02107170Phase 4
6TACT-NAGOYA: Therapeutic Angiogenesis Using Cell TransplantationUnknown statusNCT00145262Phase 2
7Safety and Efficacy Study of Autologous BM-MNC Processed by Two Methods for Treating Patients With Chronic Limb IschemiaUnknown statusNCT01446055Phase 1, Phase 2
8Autologous Bone Marrow For Lower Extremity Ischemia TreatingCompletedNCT00753025Phase 2
9A Safety/Efficacy Study of Alprostadil Liposomes for Injection to Treat Lower Extremity Arteriosclerosis ObliteransRecruitingNCT02877173Phase 2
10Effectiveness and Safety of Adipose-Derived Regenerative Cells for the Treatment of Critical Lower Limb IschemiaEnrolling by invitationNCT02864654Phase 1, Phase 2
11Study to Assess the Efficacy and Safety of CLBS12 in Patients With Critical Limb Ischemia (CLI)Not yet recruitingNCT02501018Phase 2
12Preoperative Heart Rate Variability and Baroreflex Sensitivity in ASO Patients During Various Sleep StagesCompletedNCT00712946
13HELP-Apheresis in Diabetic Ischemic Foot Treatment (H.A.D.I.F)CompletedNCT01518205
14ADDICTAO: Psychological and Addictive Profile of Patients With Buerger's DiseaseCompletedNCT01064206
15Long Superficial Femoral Artery Stenting With SuperA Interwoven Nitinol StentsRecruitingNCT03020290
16Purified CD34+ Cells Versus Peripheral Blood Mononuclear Cells in Treatment of Critical Limb IschemiaRecruitingNCT02089828
17Arterial Calcification in the DiabetesActive, not recruitingNCT02431234

Search NIH Clinical Center for Arteriosclerosis Obliterans

Inferred drug relations via UMLS68/NDF-RT46:


Cochrane evidence based reviews: arteriosclerosis obliterans

Genetic Tests for Arteriosclerosis Obliterans

About this section

Anatomical Context for Arteriosclerosis Obliterans

About this section

MalaCards organs/tissues related to Arteriosclerosis Obliterans:

36
Heart, Smooth muscle, Skin, Bone, Bone marrow, Endothelial, T cells

Publications for Arteriosclerosis Obliterans

About this section

Articles related to Arteriosclerosis Obliterans:

(show top 50)    (show all 241)
idTitleAuthorsYear
1
Emerging Novel Biomarkers for Arteriosclerosis Obliterans. (26632166)
2016
2
Baseline Characterization of Japanese Peripheral Arterial Disease Patientsa88- Analysis of Surveillance of Cardiovascular Events in Antiplatelet-Treated Arteriosclerosis Obliterans Patients in Japan (SEASON). (26841805)
2016
3
A Rare Complication of Spinal Cord Ischemia Following Endovascular Aneurysm Repair of an Infrarenal Abdominal Aortic Aneurysm with Arteriosclerosis Obliterans: Report of a Case. (27738476)
2016
4
Investigating the Role of the Posttranscriptional Gene Regulator MiR-24- 3p in the Proliferation, Migration and Apoptosis of Human Arterial Smooth Muscle Cells in Arteriosclerosis Obliterans. (26159387)
2015
5
MicroRNA-133a in the Development of Arteriosclerosis Obliterans. (25740337)
2015
6
Logistic Regression Analysis of Depression in Arteriosclerosis Obliterans Patients and Its Risk Factors. (26564507)
2015
7
Beraprost Sodium Protects Against Diabetic Nephropathy in Patients with Arteriosclerosis Obliterans: A Prospective, Randomized, Open-label Study. (25959199)
2015
8
Altered Plasma MicroRNAs as Novel Biomarkers for Arteriosclerosis Obliterans. (26370316)
2015
9
Involvement of MicroRNA-133a in the Development of Arteriosclerosis Obliterans of the Lower Extremities via RhoA Targeting. (25445891)
2014
10
MiR-142-3p attenuates the migration of CD4a8_ T cells through regulating actin cytoskeleton via RAC1 and ROCK2 in arteriosclerosis obliterans. (24743945)
2014
11
Prospective study of sarpogrelate hydrochloride on patients with arteriosclerosis obliterans. (23364237)
2013
12
Long-term effects of beraprost sodium on arteriosclerosis obliterans: a single-center retrospective study of Japanese patients. (23749750)
2013
13
Relationship between Arteriosclerosis Obliterans and the Ratio of Serum Eicosapentaenoic Acid to Arachidonic Acid. (23364231)
2013
14
A randomized, open-label, multicentre study to evaluate plasma atherosclerotic biomarkers in patients with type 2 diabetes mellitus and arteriosclerosis obliterans when treated with Probucol and Cilostazol. (23097651)
2012
15
Increment of cerebral blood flow by LDL-apheresis in dialysis patients with arteriosclerosis obliterans: a pilot study. (23065872)
2012
16
Retrograde perfusion of the hind leg in diabetic patients suffering from arteriosclerosis obliterans: theoretical considerations of oxygen supply and lymphatic flow based on rat models. (22259111)
2012
17
MicroRNA-21 regulates vascular smooth muscle cell function via targeting tropomyosin 1 in arteriosclerosis obliterans of lower extremities. (21817107)
2011
18
Characteristics of revascularization treatment for arteriosclerosis obliterans in patients with and without hemodialysis. (20938099)
2010
19
The efficacy of oral beraprost sodium, a prostaglandin I2 analogue, for treating intermittent claudication in patients with arteriosclerosis obliterans. (20357749)
2010
20
Study design of SEASON registry: prospective Surveillance of cardiovascular Events in an Antiplatelet-treated arterioSclerosis Obliterans patients in JapaN )SEASON). (20966606)
2010
21
Current status of the medical expenses for the treatment of arteriosclerosis obliterans in Japan. (20357751)
2010
22
Evaluation of proinflammatory cytokines in chronic lower limb ischaemia diabetic macroangiopathy and arteriosclerosis obliterans]. (20120706)
2009
23
Tc-99m-MIBI scintigraphy in evaluating the effect of hepatocyte growth factor gene therapy for peripheral arteriosclerosis obliterans. (19225945)
2009
24
Serum adiponectin and markers of endothelial injury in hemodialysis patients with arteriosclerosis obliterans. (18175063)
2008
25
Detecting vulnerable plaque of arteriosclerosis obliterans by multidetector-row computed tomography--comparing with VH (virtual histology)-intravascular ultrasound. (17512620)
2008
26
Long-term follow-up of Symphony nitinol stents in iliac arteriosclerosis obliterans. (18270875)
2008
27
Changes in the activities of daily living (ADL) in relation to the level of amputation of patients undergoing lower extremity amputation for arteriosclerosis obliterans (ASO). (18724029)
2008
28
Arteriosclerosis obliterans associated with anti-cardiolipin antibody/beta2-glycoprotein I antibodies as a strong risk factor for ischaemic heart disease in patients with systemic lupus erythematosus. (18375400)
2008
29
Serum levels of S-glutathionylated proteins as a risk-marker for arteriosclerosis obliterans. (17186986)
2007
30
Randomised comparison of G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. (18064333)
2007
31
Effects of selective LDL apheresis on plasma concentrations of ICAM-1, VCAM-1 and P-selectin in diabetic patients with arteriosclerosis obliterans and receiving maintenance hemodialysis. (17126824)
2007
32
Quality of life improvement and long-term effects of peripheral blood mononuclear cell transplantation for severe arteriosclerosis obliterans in diabetic patients on dialysis. (17652880)
2007
33
Intractable wounds caused by arteriosclerosis obliterans with end-stage renal disease treated by aggressive debridement and epidermal grafting. (17637445)
2007
34
Efficacy of low-density lipoprotein apheresis in arteriosclerosis obliterans of the lower extremities: two cases with marked alleviation of clinical symptoms. (17610290)
2007
35
Angiotensin I-converting enzyme inhibitor improves reactive hyperemia in elderly hypertensives with arteriosclerosis obliterans. (17249520)
2006
36
Autoperipheral blood mononuclear cell transplantation improved giant ulcers due to chronic arteriosclerosis obliterans. (16865304)
2006
37
Cost-effectiveness of Liple (LipoPGE1) for arteriosclerosis obliterans patients in Japan: an economic evaluation using the EQ-5D instrument. (16763534)
2006
38
Close association of hypoadiponectinemia with arteriosclerosis obliterans and ischemic heart disease. (15877296)
2005
39
Prevalence of asymptomatic arteriosclerosis obliterans and its relationship with risk factors in inhabitants of rural communities in Japan: Tanno-Sobetsu study. (15488869)
2004
40
Clinical application of bone marrow implantation in patients with arteriosclerosis obliterans, and the association between efficacy and the number of implanted bone marrow cells. (15564705)
2004
41
Autologous transplantation of peripheral blood stem cells as an effective therapeutic approach for severe arteriosclerosis obliterans of lower extremities. (14983238)
2004
42
Platelet activation markers, microparticles and soluble adhesion molecules are elevated in patients with arteriosclerosis obliterans: therapeutic effects by cilostazol and potentiation by dipyridamole. (15203718)
2004
43
The effect of Liple on physical and emotional quality of life in the treatment of arteriosclerosis obliterans. (15765038)
2004
44
Low-density lipoprotein apheresis in a patient with arteriosclerosis obliterans and light chain deposition disease. (15224807)
2004
45
Effect of the serotonin blocker sarpogrelate on circulating interleukin-18 levels in patients with diabetes and arteriosclerosis obliterans. (15080020)
2004
46
Three cases of ischemic ulcer due to arteriosclerosis obliterans responding to basic fibroblast growth factor spray. (15372302)
2004
47
Effects of low-density lipoprotein apheresis on plasma matrix metalloproteinase-9 and serum tissue inhibitor of metalloproteinase-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans. (12918586)
2003
48
Percutaneous transluminal angioplasty against arteriosclerosis obliterans in dialysis patients. (12579341)
2003
49
Effect of low-density lipoprotein apheresis on plasma endothelin-1 levels in diabetic hemodialysis patients with arteriosclerosis obliterans. (14583180)
2003
50
Peripheral macrohemodynamics in patients with lower limb arteriosclerosis obliterans and type II diabetes mellitus. (12811388)
2003

Variations for Arteriosclerosis Obliterans

About this section

Expression for genes affiliated with Arteriosclerosis Obliterans

About this section
Search GEO for disease gene expression data for Arteriosclerosis Obliterans.

Pathways for genes affiliated with Arteriosclerosis Obliterans

About this section

Pathways related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

(show all 21)
idSuper pathwaysScoreTop Affiliating Genes
19.8ICAM1, VCAM1
29.7ADIPOQ, IL6
39.4ICAM1, IL6, SELP
49.4ICAM1, IL6, SELP
59.4ICAM1, IL6, VCAM1
6
Show member pathways
9.4ICAM1, IL6, VCAM1
79.4ICAM1, IL6, VCAM1
89.4ICAM1, IL6, VCAM1
99.4ICAM1, IL6, VCAM1
109.4ADIPOQ, IL6, VCAM1
11
Show member pathways
9.3ITGA4, VCAM1
129.2HGF, IL6, VCAM1
139.0ICAM1, ITGA4, VCAM1
149.0ICAM1, ITGA4, VCAM1
159.0ICAM1, ITGA4, VCAM1
16
Show member pathways
9.0ICAM1, ITGA4, VCAM1
178.9HGF, ICAM1, IL6, VCAM1
18
Show member pathways
8.8IL6, ITGA4, TPM1
198.7ICAM1, ITGA4, SELP, VCAM1
208.6ICAM1, IL6, ITGA4, VCAM1
218.6HGF, ICAM1, IL6, SELP, VCAM1

GO Terms for genes affiliated with Arteriosclerosis Obliterans

About this section

Cellular components related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1external side of plasma membraneGO:00098979.8ICAM1, IL6, SELP, VCAM1
2cell surfaceGO:00099869.3ADIPOQ, ICAM1, ITGA4, VCAM1
3extracellular spaceGO:00056158.2ADIPOQ, HGF, ICAM1, IL6, SELP, VCAM1

Biological processes related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

(show all 31)
idNameGO IDScoreTop Affiliating Genes
1calcium-mediated signaling using intracellular calcium sourceGO:003558410.6SELP, VCAM1
2membrane to membrane dockingGO:002261410.5ICAM1, VCAM1
3acute inflammatory responseGO:000252610.5IL6, VCAM1
4cellular response to dexamethasone stimulusGO:007154910.5ICAM1, IL6
5cellular response to nutrient levelsGO:003166910.5ICAM1, IL6
6positive regulation of nitric oxide biosynthetic processGO:004542910.4ICAM1, IL6
7negative regulation of fat cell differentiationGO:004559910.4ADIPOQ, IL6
8negative regulation of gluconeogenesisGO:004572110.4ADIPOQ, IL6
9negative regulation of hormone secretionGO:004688810.4ADIPOQ, IL6
10response to amino acidGO:004320010.4ICAM1, IL6
11negative regulation of extrinsic apoptotic signaling pathway via death domain receptorsGO:190204210.3HGF, ICAM1
12cellular response to hepatocyte growth factor stimulusGO:003572910.3HGF, IL6
13heterophilic cell-cell adhesion via plasma membrane cell adhesion moleculesGO:000715710.2ICAM1, SELP, VCAM1
14positive regulation of vasoconstrictionGO:004590710.2HTR2A, ICAM1
15cellular response to tumor necrosis factorGO:007135610.1ICAM1, IL6, VCAM1
16positive regulation of leukocyte migrationGO:000268710.1ITGA4, SELP
17response to ethanolGO:004547110.1ADIPOQ, ICAM1, VCAM1
18response to hypoxiaGO:000166610.0ADIPOQ, ICAM1, VCAM1
19cellular response to cytokine stimulusGO:007134510.0IL6, ITGA4
20regulation of cell shapeGO:000836010.0ICAM1, IL6, TPM1
21agingGO:00075689.9HTR2A, IL6, VCAM1
22positive regulation of ERK1 and ERK2 cascadeGO:00703749.8HTR2A, ICAM1, IL6
23leukocyte tethering or rollingGO:00509019.8ITGA4, SELP, VCAM1
24leukocyte migrationGO:00509009.7ICAM1, ITGA4, SELP
25extracellular matrix organizationGO:00301989.7ICAM1, ITGA4, VCAM1
26regulation of immune responseGO:00507769.7ICAM1, ITGA4, VCAM1
27cell adhesionGO:00071559.4ICAM1, ITGA4, SELP, VCAM1
28leukocyte cell-cell adhesionGO:00071599.4ICAM1, ITGA4, SELP, VCAM1
29response to drugGO:00424939.4ADIPOQ, HTR2A, ICAM1, IL6
30response to lipopolysaccharideGO:00324969.1ICAM1, IL6, SELP, VCAM1
31positive regulation of peptidyl-tyrosine phosphorylationGO:00507318.9ADIPOQ, HGF, HTR2A, ICAM1, IL6

Molecular functions related to Arteriosclerosis Obliterans according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1sialic acid bindingGO:00336919.8ADIPOQ, SELP

Sources for Arteriosclerosis Obliterans

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet